DUBLIN, Ireland, Sept. 11, 2017 -- Horizon Pharma plc (NASDAQ:HZNP), a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today named Irina Konstantinovsky executive vice president, chief human resources officer, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately.
“Irina is an accomplished human resources professional with an excellent track record of attracting, developing and retaining talent as well as building an inclusive and engaging culture,” said Walbert. “Her extensive experience will be critical as the company continues to grow and evolve.”
Prior to Horizon, Konstantinovsky was vice president of global talent at Baxter International Inc. where she led a team of talent professionals worldwide and oversaw organizational effectiveness, leadership development, inclusion and diversity and talent acquisition. She and her team were responsible for talent management strategies, programs and systems for more than 50,000 employees worldwide.
“Horizon Pharma has a strong, patient-centered culture with passionate, committed employees at its core,” said Konstantinovsky. “I’m looking forward to helping build a world-class human resources function that continues to foster and develop these strengths.”
Prior to Baxter, Konstantinovsky spent 15 years in senior partner and director roles at Towers Watson (currently Willis Towers Watson), a global human resources consulting firm serving Fortune 1000 companies. While in these roles, she served as the interim chief human resource officer at Capital BlueCross for two years.
She has a Bachelor of Arts in Education from the University of Buenos Aires and master’s degrees in higher education and industrial and labor relations from Cornell University. In addition, Konstantinovsky serves on the board of the Human Resource Management Association of Chicago.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 



